Substance P Dosing & Reconstitution Guide

Given that Substance P is an endogenous neuropeptide, conventional dosing protocols applicable to exogenous compounds do not apply. In research contexts, studies have reported the administration of Substance P in a range of 10–100 pmol via intravenous bolus in human subjects. This range reflects the concentrations typically utilized in clinical trials assessing its role in pain modulation and other physiological effects. Researchers should be aware that variations in individual response and the specific context of each study can influence the effective dose. Careful consideration of the experimental design and objectives is essential when determining the appropriate use of Substance P in laboratory settings.

As an endogenous neuropeptide, Substance P is not typically administered as a therapeutic agent, and thus, conventional safety assessments for drugs do not apply. However, it is important to note that exogenous administration of Substance P has been associated with adverse effects, including pain at the injection site, flushing, and hypotension. These effects underscore the necessity for caution when considering the use of Substance P in experimental models. NK1 receptor antagonists, which target the same pathways as Substance P, have been extensively studied and exhibit well-characterized safety profiles, providing insights into potential risks. Given that this entry serves as a reference for an endogenous neuropeptide, there are no specific contraindications associated with its use in therapeutic contexts.